FEATURED ARTICLES

• Solving Segregation Effects In Solid-Dosage Form Operations

  Understanding segregation and how it is related to drug development cost is at the heart of solving this issue and is the topic of this article.

• Early Detection Of Powder Flowability Challenges In Formulation Development Of Solid Dosage Forms
• How To Increase Regulatory Flexibility And Tablet Production Efficiency
• The Key To Continuous Manufacturing
• Accurate Bulk Density Measurement Maximizes Solid Dose Production

WHITE PAPERS & CASE STUDIES

• Enabling Complex Phase IIa Dosing Through Flexible Clinical Packaging Design

  Discover how flexible, patient‑centric clinical packaging supports complex Phase IIa dosing while protecting timelines, ensuring compliance, and avoiding costly primary packaging changes.

• Achieving Licensing For A Healthcare Solution

  Facing strict regulations and tricky powders, a healthcare client sought an advanced filling solution. Learn how an expert collaboration led to licensed product, boosting precision and productivity.

• Optimizing DPI Production: Filling Technologies For Precision And Performance

  Developing effective dry powder inhalers requires expertise across multiple disciplines, from particle engineering and device technology to manufacturing science and regulatory knowledge.

• How To Avoid Sticking And Picking In The Tableting Industry

  Review strategies to mitigate sticking and picking risks in the tablet industry, and learn how you can foster improved tablet production processes, ensuring higher quality and consistency.

• Overload Setting – Tricks And Techniques

  Learn how a partner company that is committed to assisting manufacturers with calibration and optimal set-point establishment can serve as a valuable resource in achieving optimal tablet production.

• Intro To USP <1062> - What It Is And Why You Should Use It

  Knowing how to use USP <1062> helps manufacturers manage the wide variety of factors that can exacerbate production costs, or result in no product at all.